Drug Store News has rounded up all the retail pharmacy comings and goings to help keep you informed. Here are this week’s announcements.
The Pharmaceutical Research and Manufacturers of America names Novartis CEO Vas Narasimhan, M.D., to board chair
The Pharmaceutical Research and Manufacturers of America (PhRMA) has announced that Novartis CEO Vas Narasimhan, M.D., has assumed the role of chair of the PhRMA board of directors.
In addition, Daniel O'Day of Gilead Sciences and Albert Bourla of Pfizer also assumed new leadership positions on the PhRMA board.
“Science and technology are advancing at an unprecedented pace, leading to significant breakthroughs in medicine. Pushing the cutting edge through R&D, the biopharmaceutical industry brings forward revolutionary treatments and cures, and our association and industry work to ensure patients have access to the medicines they need to live longer, healthier lives,” said Dr. Narasimhan. “It’s in the best interest of patients, health systems, and society at large for government to foster a robust innovation ecosystem through policies that support—rather than discourage—the development of better treatment options and widespread patient access. I’m eager to help lead the association at this pivotal moment for patients and our industry.”
Dr. Narasimhan has been CEO of Novartis since 2018, leading the company in delivering medicines that alleviate some of society’s greatest disease burdens through novel access approaches and technology leadership in R&D, PhRMA said. Since joining Novartis in 2005, Narasimhan has held a range of leadership roles, including Global Head of Drug Development and Chief Medical Officer, and Global Head of Development for Novartis Vaccines.
“The new treatments for patients coming out of labs today would have been considered science fiction just a decade ago. But the policy environment threatens this progress, adding to the waiting and uncertainty facing patients hoping for treatments and cures,” said PhRMA president and CEO Stephen J. Ubl. “From his work as a physician addressing global public health issues to his time as a researcher to his vast business experience, Vas is well-positioned for the job of board chair. I look forward to working closely with him and our board as we continue pushing for policies that address the broader affordability challenges patients face while protecting the pipeline of potentially game-changing medicines.
Robert G. Miller has joined the board of Save Mart Co.
The Save Mart Companies, a Kingswood Capital Management portfolio company, recently announced the appointment of former Rite Aid and Albertsons executive, Robert G. Miller ("Bob"), to its board of directors.
"Bob's expertise and passion for the grocery industry is legendary along with his unparalleled track record of being a growth-focused leader," said Shane Sampson, executive chairman of the board, The Save Mart Companies. "For decades, Bob has built great companies by always being people and community focused as well as mentoring countless individuals including myself, and I am excited to once again collaborate with him and further advance the company's success together."
Miller said: "I am incredibly grateful and honored to join The Save Mart Companies board of directors at a time when there is so much opportunity in the grocery industry for growth. This company and its people exemplify the hard-working and passionate spirit of running great stores and serving their communities."